Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Presentation (October 2019)
81 slides from Orion Oyj Class A's investor presentation, October 2019
Slide 1: Orion Investor Presentation
Orion Investor Presentation
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Content
Content 1) Orion in brief 2) R&D 3) Highlights of 1−9/2019 4) Outlook and financials 5) Businesses 6) Sustainability 7) Financial calendar Investor Presentation © Orion Corporation 3
Slide 4: Orion in brief
Orion in brief Investor Presentation © Orion Corporation
Slide 5: Key messages
Key messages 11 3 5 Orion develops, Growth targeted Strong position in manufactures and through new the Nordic markets human in-house developed generics market. and animal drugs. pharmaceuticals, and APIs. Products marketed in >100 countries. 6 Core therapy areas 22 4 4 Balanced business Strong mode
Slide 6: Orion at a glance (2018 figures)
Orion at a glance (2018 figures) Net sales Sales by business Sales by market area 977 MEUR Operating profit 5% 2% 15% 8% 253 MEUR 37% 32% 6% Personnel 3,154 R&D investments 48% 31% 104 MEUR 16% 6 production sites in Finland Proprietary Products Finland Scandinavia Specialty Products Other Europe Own
Slide 7: Steady development despite patent expiries
Steady development despite patent expiries Net sales Operating profit EUR million EUR million 1,200 12% 350 32% 1,000 9% 300 31% 800 6% 250 30% 200 29% 600 3% 150 28% 400 0% 100 27% 200 -3% 50 26% 0 -6% 0 25% 2011 2012 2013 2014 2015 2016 2017 2018 Parkinson franchise + Precedex Operating profit Oth
Slide 8: Orion’s product mix has changed
Orion’s product mix has changed Sales by business 2011 Sales by business 2018 Net sales, EUR million 3% 5% 2% 5% 1,200 8% 8% 1,050 47% 37% 900 750 600 450 37% 48% 300 150 0 Proprietary Products Specialty Products Animal Health Fermion Contract manufacturing & other Investor Presentation © Orion Corp
Slide 9: Our businesses
Our businesses 1 Proprietary Products Specialty Products In-house developed drugs and other drugs with valid product 3 Generic prescription drugs, OTC and non-medicinal 5 protection products, biosimilars Animal Health Fermion Medicine and well-being Active pharmaceutical products for animals ingredi
Slide 10: Orion’s strategy – Mission to build well-being
Orion’s strategy – Mission to build well-being Growth Sustainability Investor Presentation © Orion Corporation 10
Slide 11: Key strategic target in 2019−2023: Growing more rapidly than the market
Key strategic target in 2019−2023: Growing more rapidly than the growth in the market 1 Net sales target Own investments in Investments in sales in 2025 new clinical trials: and marketing: E.g. EUR 60 million E.g. strengthening 1.5 investment in Phase III trial on ALS (REFALS). the Easyhaler® produc
Slide 12: Orion had ~69,000 shareholders on 30 September 2019
Orion had ~69,000 shareholders on 30 September 2019 By number of shares By number of votes Households (Finnish 4% 0% retail) 3% 5% 9% Non-Finnish holders and 8% 6% nominee-registered Private corporations 7% 41% 13% Public sector 62% Non-profit institutions 7% 35% Financial and insurance corporations
Slide 13: Research and development
Research and development Investor Presentation © Orion Corporation
Slide 14: Focus areas of Orion’s R&D
Focus areas of Orion’s R&D Proprietary products Animal Health Fermion • Central nervous system • Orion utilises the • APIs to Orion’s • Oncology R&D of proprietary proprietary products • Respiratory products to develop • Generic APIs (Easyhaler® product family) new medicines for • Contract developme
Slide 15: Together we can achieve more in R&D
Together we can achieve more in R&D Late stage Research Early development development Target Hit to Lead Lead Candidate Phase I Phase II Phase III identification generation optimisation selection, and validation preclinical development 8‒24 mo. 12‒24 mo. 18‒36 mo. 12‒24 mo. 12‒14 mo. 12‒36 mo. 18‒48
Slide 16: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Registration Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targe
Slide 17: ARAMIS trial: Efficacy and safety of darolutamide in nmCRPC
ARAMIS trial: Efficacy and safety of darolutamide in non- metastatic castration- resistant prostate cancer
Slide 18: Orion and Bayer’s phase III trial of darolutamide for nmCRPC
Orion and Bayer’s phase III trial of darolutamide for non-metastatic castration- resistant prostate cancer ● Darolutamide was approved in the USA ● Detailed data presented at under the FDA Priority Review the ASCO GU 2019 and in the designation in July 2019. New England Journal of Medicine. ● The ap
Slide 19: Financial impacts of darolutamide
Financial impacts of darolutamide ● Bayer has the right to commercialize darolutamide globally. ● Orion has the option of co-promoting in Europe. Orion will manufacture the product. ● Milestone payments upon first commercial sales: • EUR 45 million in the US – Q3/2019 • EUR 20 million in the EU • EU
Slide 20: Non-metastatic castration-resistant prostate cancer (nmCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC) ● A form of prostate cancer associated with rising PSA (Prostate-Specific Antigen) levels despite androgen deprivation therapy (ADT). ● The cancer has not yet spread beyond the prostate region. ● High risk for progression to metastatic dis
Slide 21: Until recently, no effective treatment options for CRPC patients
Until recently, there have been no effective treatment options for CRPC patients who have rising Prostate-Specific Antigen (PSA) levels while on ADT and no detectable metastases Non-metastatic CRPC 21
Slide 22: Darolutamide has demonstrated low blood-brain barrier penetration
Darolutamide has demonstrated low blood-brain barrier penetration that may lead to lower incidence of adverse events ● Darolutamide is a non-steroidal androgen receptor antagonist that binds to the receptor with high affinity and inhibits the growth of prostate cancer cells. ● In preclinical studies
Slide 23: ARAMIS Phase III trial design
ARAMIS Phase III trial design 1,200 mg darolutamide + ADT Randomization 1,509 patients (600 mg twice a day) − 955 patients Men with nmCRPC currently 2:1 being treated with ADT, and at high risk for developing Placebo twice a day + ADT metastatic disease − 554 patients Primary endpoint Secondary endp
Slide 24: Darolutamide shows substantial efficacy and favourable safety profile
Summary of results: Darolutamide shows substantial efficacy and favourable safety profile ● Darolutamide significantly improves ● Darolutamide has a favorable metastasis-free survival (MFS): safety profile: – Median 40.4 months with darolutamide – It didn’t increase rates of critical adverse vs 18.4
Slide 25: ARASENS trial continues to expand indication to metastatic prostate cancer
ARASENS trial continues in order to expand the indication to metastatic prostate cancer Patients Endpoints ● Men with metastatic, hormone-sensitive ● Primary: prostate cancer Darolutamide over placebo Treatment in overall survival ● Darolutamide plus ● Secondary: androgen deprivation therapy Time to
Slide 26: Global prostate cancer estimates (2018)
Global prostate cancer estimates (2018) 70 12nd 35th 5 most commonly leading cause of diagnosed death from cancer malignancy in men 50 60 70 80 in men worldwide 50 60 70 80 21.2 million men 358,000 died from 4 6 50+ Mainly affects men diagnosed with the disease over 50, the risk prostate cancer incr
Slide 27: ODM-109: Oral levosimendan for ALS
ODM-109: Oral levosimendan for ALS ● First patients recruited in July 2018 ● The aim is to apply for marketing authorisation for the Phase III clinical trial (REFALS). in the USA and Europe. ● By enhancing respiratory muscle function ● Levosimendan has been granted an Orphan Drug in ALS patients, or
Slide 28: REFALS patient recruitment completed
REFALS patient recruitment completed 104 ALS centres in 14 countries • REFALS is an Orion study Primary endpoints • 1st patient randomised July 2018 • 12 weeks: Slow vital capacity • Last patient randomisation in July 2019 (Breathing – Study results expected in H2 2020 capacity compared • Number of
Slide 29: ALS as a rare disease
ALS (Amyotrophic lateral sclerosis) as a rare disease 1−2∕ ~16,800 ~12,500 ~450−500 100,000 Patients Incidence Patients Patients in the US in 2017 in Europe in Finland Investor Presentation © Orion Corporation 29
Slide 30: CYP11A1 inhibitors (ODM-208 and ODM-209)
CYP11A1 inhibitors (ODM-208 and ODM-209) ● First-in-class compounds CHOLESTEROL ● Orion leads the development in the world CYP11A1 INHIBITOR ● CYP11A1-inhibitors prevent the synthesis of ALL steroid hormones ● Glucocorticoids and mineralocorticoids need to be replaced during therapy PREGNENOLONE All
Slide 31: CYP11A1 inhibitors have wide potential indications
CYP11A1 inhibitors have wide potential indications ● Prostate cancer (1.3 million cases/year; the 2nd most common cancer in males in the world1) ● 70% of breast cancers (estrogen receptor-positive cancers; 1.5 million cases/year; the most common cancer in females1) ● Endometrial cancer of the uterus
Slide 32: Orion investigates CYP11A1 inhibitors in two first-in-human Phase I-II trials
Orion investigates CYP11A1 inhibitors in two first-in-human Phase I-II trials The CYPIDES trial (ODM-208) The STESIDES trial (ODM-209) • Advanced prostate cancer that • Advanced prostate cancer that progressed during ≥1 novel progressed during one or more novel hormonal therapy and hormonal therapy
Slide 33: ODM-208: Pan-steroid hormone synthesis inhibitor for prostate cancer
ODM-208: Pan-steroid hormone synthesis inhibitor (CYP11A1 inhibitor) for castration-resistant prostate cancer ● Steroid hormones stimulate the growth of hormonally regulated cancers, such as most prostate and breast cancers. ● Hormonal treatments are highly effective, but Steroid producton drug resi
Slide 34: Highlights in January–September 2019
Highlights in January–September 2019
Slide 35: Marketing authorisation for darolutamide in the USA
Marketing authorisation for darolutamide in the USA – application review ongoing in other main markets 1 Marketing authorisation granted for darolutamide in the USA. Application review ongoing in 3 Easyhaler® and Simdax® showing strong performance. Specialty Products’ net sales Europe, Japan and oth
Slide 36: Key figures 1−9/2019
Key figures 1−9/2019 Net sales Operating profit Operating profit Cash flow per share margin before financial items* 776 198 25% 1.28 MEUR (715) MEUR (184) (26%) EUR (2.10) +9% +7% -39% *) Comparison period cash flow per share before financial items includes both continuing and discontinued operation
Slide 37: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 4 776 37 -2 -18 4 15 11 37 -9 198 13 -10 715 -5 184 3 -5 * Product sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix chan
Slide 38: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-9/2019 MEUR 1-9/2019 1-9/2018 11% 300 +12% 29% -2% 250 11% 200 150 +14% -21% +108% 100 32% 17% 50 0 Finland Scandinavia Other Europe North America ROW Investor Presentation © Orion Corporation 38
Slide 39: Growth in all business divisions
Growth in all business divisions 1−9/2019 1−9/2018 1-9/2019 MEUR +1% 400 +18% 5% 2% 349 347 350 8% 308 300 261 40% 250 +1% 200 150 +11% +14% 45% +3% 100 64 58 43 38 50 13 12 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion CM* & Animal Health Products Products Health ot
Slide 40: Best-selling pharmaceuticals 1–9/2019
Best-selling pharmaceuticals 1–9/2019 Net sales Change vs . Indication (EUR million) 1−9/2018 1. Asthma, COPD 75 +16% 2. Parkinson’s disease 70 -7% 3. Acute heart failure 49 +14% 4. Intensive care sedative 46 -5% Rheumatoid arthritis, inflammatory 5. Biosimilars bowel diseases, lymphoma 28 +47% 6. A
Slide 41: Proprietary Products
Proprietary Products
Slide 42: Easyhaler® product family and Simdax® growing
Easyhaler® product family and Simdax® growing 1-9/2019 +16% -7% MEUR 80 75 76 70 22% 23% 70 64 -5% +14% 60 46 48 49 50 43 16% 40 30 20 24% 10 15% 0 Parkinson Easyhaler® Easyhaler® Parkinson Dexdor® Simdax® franchise Dexdor® Simdax® Other 1−9/2019 1−9/2018 Investor Presentation © Orion Corporation 42
Slide 43: Easyhaler® product family will be a key source of growth
Easyhaler® product family will be a key source of growth in the next few years Sales, EUR million 30 ● Budesonide-formoterol Easyhaler® +23% 25 continued strong growth. 20 ● Product family total sales: +16% 15 10 ● Salmeterol-fluticasone sales developed slower than anticipated. 5 0 ● Development of
Slide 44: Share of Orion’s own sales in Parkinson growing
Share of Orion’s own sales in Parkinson growing Sales, EUR million 50 45 40 35 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 2016 2017 2018 2019 Orion's own sales Parkinson (Stalevo®, Comtan®) deliveries to partners Investor Presentation © Orion Co
Slide 45: Sales of Dexdor® declining due to generic competition
Sales of Dexdor® declining due to generic competition Total value of European sedatives market: Sales, EUR million EUR 585 million (+4%) 20 12% 18 16 14 12% 12 66% 10 8 6 10% 4 2 0 Propofol 383 Meur (+4%) Midazolam 61 Meur (-3%) 2014 2015 2016 2017 2018 2019 Dexmedetomidine 72 Meur (+7%) Remifentani
Slide 46: Specialty Products
Specialty Products GRION Building well-being
Slide 47: Specialty Products: tight price competition continued
Specialty Products: tight price competition continued Development of net sales Net sales by region Net sales by product 1−9/2019 1−9/2019 MEUR -1% 250 10% 8% 199 200 200 14% 25% 150 +27% +2% 57% 100 65 51 48 47 19% 50 67% 0 Finland Scandinavia Eastern Finland Generic drugs Europe and Scandinavia Rus
Slide 48: In Finland, price competition has led to decline in reference priced drugs
In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1–9/2019) in Finland MEUR 319 (342) MEUR 85 (90) Market development Or
Slide 49: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−9/2019 Self-care Medicinal and non-medicinal products Reference priced products in hospital and pharmacy channels: EUR 2,083 million prescription Orion market share in EUR million drugs pharmacy 250 229 Orion 200 137 73 market s
Slide 50: Orion's key business targets in 2019 (1–2)
Orion's key business targets in 2019 1. Preparation for the commercialisation • Marketing authorisation of darolutamide. ARASENS trial (metastatic applications submitted in the main prostate cancer) continues in order to markets. expand the indication for the molecule. • Marketing authorisation gran
Slide 51: Orion's key business targets in 2019 (3–5)
Orion's key business targets in 2019 3. Strengthening Orion’s position as the • Orion's sales volume in Finland most significant provider of generic drugs grew faster than the market. in Finland. Competitive product portfolio in Specialty Products and strengthening of product launches. 4. Accelerati
Slide 52: Outlook
Outlook
Slide 53: Investments in growth EUR 30 million in 2019
Investments in growth EUR 30 million in 2019 ● The ongoing projects ● This comprises clearly ● At the same time, operating supporting growth are increased depreciation as profit is burdened by expected to burden Orion’s well as investments in intense price competition in profit in 2019 by an sales a
Slide 54: Outlook for 2019
Outlook for 2019 Net sales Orion estimates that in 2019 net sales will be + slightly higher than in 2018 (net sales in 2018 were EUR 977 million). The estimated net sales include the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide. Operating = profit O
Slide 55: Financials
Financials
Slide 56: Orion’s financial objectives
Orion’s financial objectives Growing net sales more rapidly than ≥ growth of the pharmaceuticals market. Achievement of this objective requires continuous investment in Keeping the equity ratio at least 50%. development of the product portfolio. Distributing an annual dividend that > Maintaining p
Slide 57: Financial objectives
Financial objectives Net sales Operating profit Dividend 1,200 12% 35% 1.60 300 30% 1.55 1,000 9% 250 25% 1.50 800 6% 200 1.45 20% 1.40 600 3% 150 15% 1.35 400 0% 100 1.30 10% 1.25 200 -3% 50 5% 1.20 0 -6% 0 0% 1.15 2012 2013 2014 2015 2017 2018 2016* 2012 2013 2014 2015 2016 2017 2018 2012 2013 201
Slide 58: Key figures by quarter
Key figures by quarter Net Netsales, sales,EUR EURmillion million Operating Operating profit, profit, EUREUR million million 1,500 Q4 400 Q4 1,000 262 300 59 Q3 280 262 266 264 Q3 55 51 71 238 239 259 242 284 200 92 69 Q2 222 Q2 64 59 55 500 45 91 277 255 273 261 246 252 86 74 84 71 Q1 100 70 52 245
Slide 59: Key figures
Key figures 1-9/ Change vs. Orion’s key figures 2014 2015 2016 2017 2018 2019 1-9/2018 Net sales, EUR million 1,015.3 1,015.6 1,073.5 1,033.6 977.5 492.8 -0.1% EBITDA 293.9 239.3 +11.8% Operating profit, EUR million 272.4 266.6 314.6 284.1 252.8 197.8 +7.4% Profit before taxes, EUR million 267.8 262
Slide 60: Income statement
Income statement Change vs. Formation of profits, EUR million 2014 2015 2016 2017 2018 1-9/2019 1-9/2018 Net sales 1,015.3 1,015.6 1,073.5 1,033.6 977.5 776.5 +8.6% Cost of goods sold -401.7 -405.8 -421.7 -417.6 -387.9 -304.6 +6.3% Gross profit 613.6 609.8 651.8 616.0 589.6 471.9 +10.1% Other operat
Slide 61: Financial position
Financial position EUR million 9/19 9/18 Change % EUR million 9/19 9/18 Change % Non-current assets total 409.9 415.3 -1.3% Inventories 229.3 220.0 +4.2% Equity total 712.1 736.8 -3.4% Interest-bearing non-current Trade receivables 176.6 165.4 +6.8% liabilities 5.1 0.6 Other receivables 22.4 33.2 -3
Slide 62: Development of capital expenditure
Development of capital expenditure Orion Capex, EUR million 90 80 70 60 50 Property, plant and equipment 40 30 Intangible assets 20 Depreciation, amortisation and 10 impairment 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 YTD9 2019 Investor Presentation © Orion Corporation 62
Slide 63: Development of net working capital
Development of net working capital % of net sales EUR million 40% 400 30% 300 20% 200 10% 100 0% 0 -10% -100 -20% -200 -30% -300 2012 2013 2014 2015 2016 2017 2018 2019 2012 2013 2014 2015 2016 2017 2018 2019 Receivables Receivables Inventories Inventories Short-term non-interest bearing liabilities
Slide 64: Dividend distribution policy
Dividend distribution policy • Orion’s dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives. EUR Dividend distribution history 1.75 0.20 100% 1.50 0.06 0.12 95% 1.25 90% 0.10
Slide 65: Orion B share performance January 2016 – October 2019
Orion B share performance January 2016 – October 2019 Index 31/12/2015=100 200 180 160 140 Orion B 120 Orion B total return Europe/Pharmaceutical 100 OMXH-portfolio 80 60 31-Dec-15 31-Mar-16 30-Jun-16 30-Sep-16 31-Dec-16 31-Mar-17 30-Jun-17 30-Sep-17 31-Dec-17 31-Mar-18 30-Jun-18 30-Sep-18 31-Dec-18
Slide 66: Business units
Business units Building well-being
Slide 67: Proprietary Products: In-house developed prescription drugs
Proprietary Products: In-house developed prescription drugs with valid product protection Net sales EUR million 400 Global sales and Other 350 R&D partner Simdax® networks 300 250 Easyhaler® 200 150 Dexdor® 100 Precedex® Key drivers: 50 0 Stalevo®/Comte Easyhaler®, Simdax® Generic competition 2012 2
Slide 68: Proprietary human pharmaceuticals developed by Orion
Proprietary human pharmaceuticals developed by Orion Fareston® * *) Nubeqa® currently only approved in the USA Investor Presentation © Orion Corporation 68
Slide 69: Diverse treatment options for asthma and COPD using the same inhaler technology
Diverse treatment options for asthma and COPD by utilizing the same inhaler technology ● Easyhaler® is a dry-powder inhaler developed in-house ● Orion has developed Easyhaler-adapted dry powder formulations of several well-known generic active substances: – salbutamol, beclometasone, budesonide, for
Slide 70: Easyhaler® product family is expanding
Easyhaler® product family is expanding 2018 Tiotropium development started Investor Presentation © Orion Corporation 70
Slide 71: Specialty Products: Generic prescription drugs, biosimilars and OTC
Specialty Products: Generic prescription drugs, biosimilars and OTC including also non-medicinal products EUR million 550 22% 500 20% Portfolio of 18% 450 16% hundreds 14% 400 12% of products 350 10% 300 8% 6% 250 4% 200 2% 0% 150 -2% 100 -4% 50 -6% -8% 0 -10% 2017 2008 2009 2010 2011 2012 2013 2014
Slide 72: Animal Health
Animal Health EUR million 105 12% In-licensed products 90 10% sold in own sales 75 8% areas 6% 60 4% 45 2% 30 0% 15 -2% 0 -4% In-house developed Medicinal and non- 2012 2013 2014 2015 2016 2017 2018 proprietary products medicinal products for Net sales Growth, % sold globally through companion anima
Slide 73: Fermion has an important strategic role
Fermion has an important strategic role EUR million 70 50% 60 40% Active 50 30% pharmaceutical 40 20% ingredients (APIs) for Orion’s own 30 10% Proprietary Products 20 0% 10 -10% 0 -20% 2010 2011 2012 2013 2014 2015 2016 2017 2018 Generic APIs for Contract Orion and other development and Net sales*
Slide 74: Fermion's new production plant operational in Hanko
Fermion's new production plant operational in Hanko – nearly 100% of production is exported ● Special expertise in demanding production of active pharmaceutical ingredients (APIs), e.g. extremely potent substances. ● The aim is to captively manufacture the APIs for Orion's in-house developed proprie
Slide 75: Contract manufacturing & other
Contract manufacturing & other EUR million 50% 40 35% Pharmaceutical 20% manufacturing for 30 5% other companies -10% 20 -25% 10 -40% -55% 0 -70% 2012 2013 2014 2015 2016 2017 2018 Net sales Growth, % Investor Presentation © Orion Corporation 75
Slide 76: Sustainability is built into Orion’s mission
Sustainability is built into Orion’s mission
Slide 77: Key themes of corporate responsibility
Key themes of corporate responsibility Responsibility Ensure patient for the environment Ethics and safety and – production according Taking care of transparency of availability of to the principles Orionees operations medicines of sustainable development Investor Presentation © Orion Corporation 77
Slide 78: This is how we are building well-being responsibly
This is how we are building well-being responsibly WE PRODUCE 1/3 OF THE GLOBAL SUPPLY OF ~200-300 NUMBER OF AUDITS CUSTOMER METHOTREXATE ANNUALLY COMPLAINTS IN 2018 56 (ppm) ORION’S FOCUS ON QUALITY THROUGHOUT THE LIFECYCLE PATIENT R&D RAW MANUFACTURING PACKING DELIVERY SALES PATIENT RECYCLING NEED
Slide 79: Orion calendar
Orion calendar Financial Statement Release for 2019 5/2/2020 AGM planned to be held 25/3/2020 Interim Report 1−3/2020 28/4/2020 Half-Year Report 1−6/2020 17/7/2020 Interim Report 1−9/2020 21/10/2020
Slide 80: Investor Relations
Investor Relations Jari Karlson CFO jari.karlson@orion.fi +358 10 426 2883 Tuukka Hirvonen Head of Investor Relations tuukka.Hirvonen@orion.fi +358 10 426 2721 Heidi Ahti Executive Assistant (Investor meeting requests) heidi.ahti@orion.fi +358 10 426 2169 www.orion.fi/EN/Investors twitter.com/OrionC
Slide 81: Building well-being
Building well-being GRION Building well-being